Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Yeon-hee Park, MD,PhD
CONTACT
hyunjung shin, CRC
CONTACT
Lead
Samsung Medical Center
A, Neoadjuvant setting); 6 cycles q3weeks, intravenous(IV) administration * Docetaxel (75mg/m2, intravenous(IV)) Day(D)1 * Atezolizumab (1200mg, IV) D1 * Herceptin sc (600mg subcutaneous(SC))D1 * Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg(IV))D1 B, Adjuvant setting : 11-12 cycles q3weeks \[patients with pCR\] * Atezolizumab (1200mg, IV) * Trastuzumab (600mg, SC) * Pertuzumab (420mg, IV) D1 \[patients with non-pCR\] * Doxorubicin(60mg/m2), cyclophosphamide (600mg/m2) D1 X 4cycles 3weeks * Atezolizumab (1200mg, IV) * Trastuzumab (600mg, SC) * Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted